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PURPOSE: To evaluate the long-term safety and efficacy of posterior chamber collagen copolymer
phakic intraocular lens (pIOL) implantation to correct myopia.
SETTING: Fern!andez-Vega Ophthalmological Institute, Oviedo, Spain.
DESIGN: Cohort study.
METHODS: Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, pIOL
vault, endothelial cell loss, and adverse events were evaluated for 5 years after implantation of
the Visian Implantable Collamer Lens pIOL for moderate to high myopia.
RESULTS: The mean spherical equivalent (188 eyes) decreased from !11.17 diopters (D)G 3.40
(SD) preoperatively to!0.88G 0.72 D 5 years postoperatively. The mean change in refraction from
1month to 5 years was!0.65G 0.65 D. Themean UDVA and CDVA (Snellen decimal) were 0.69G
0.26 and 0.83G 0.15, respectively. The mean safety and efficacy indices were 1.27G 0.33 and
0.89 G 0.35, respectively. No eye lost more than 2 lines of visual acuity; 70% achieved 0.80 or
better CDVA. Three eyes (1.6%) developed late anterior subcapsular cataract that was clinically
significant in 1 case, leading to pIOL removal and phacoemulsification. Of the 3 eyes (1.6%)
with a mild transient increase in intraocular pressure (up to 27 mm Hg), none required a second
surgical procedure or prolonged topical medication. The total endothelial cell loss (considered
cumulatively at consecutive intervals through 5 years) was 7.7%. There was a tendency toward
decreased pIOL vault decrease over time. No vision-threatening complications occurred.
CONCLUSION: Implantation of the collagen copolymer pIOL for moderate to high myopia was safe
and effective and provided long-term predictable, stable refractive results.
Financial Disclosure: No author has a financial or proprietary interest in any material or method
mentioned.
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Today, phakic intraocular lenses (pIOLs) are usually
implanted as an alternative treatment to correct ame-
tropia of various refractive ranges. An evolving tech-
nique in the field of refractive surgery, pIOL
implantation has several advantages, including fast
visual recovery, excellent refractive accuracy and
stability, improved visual acuity, preservation of ac-
commodation, and reversibility.
At present, the Visian Implantable Collamer Lens
pIOL (Staar Surgical Co.) is the only posterior chamber
pIOL approved by the United States Food and Drug
Administration (FDA) for the treatment of moderate
to severe myopia. This pIOL is of a foldable collagen
copolymer material and is designed to be placed in
the posterior chamber, behind the iris, with a haptic
zone resting on the ciliary sulcus. Several studies
report its effectiveness in correcting myopia,1–5 hyper-
opia,6,7 and astigmatism8–10 or in patients who may
not be appropriate candidates for corneal reshaping
procedures.11–14 However, in addition to the risks of
any intraocular surgery,15 the main concerns with
pIOL implantation relate to its long-term safety,
including long-term endothelial cell loss,16,17 pigmen-
tary glaucoma,18 pupillary block,19,20 and cataract for-
mation.21 Although studies of pIOL implantation
report acceptable complication and visual acuity loss
rates, few studies have spanned more than 3 years to
observe the long-term clinical and refractive
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outcomes.22,23 Long-term potential problems cannot
be dismissed because the risk for them may increase
with time. The aim of the present study was to evalu-
ate the long-term (up to 5 years) clinical and refractive
outcomes of pIOL implantation to correct moderate to
high myopia.
PATIENTS AND METHODS
This retrospective observational study included the medical
records of patients who had implantation of a Visian Im-
plantable Collamer Lens pIOL for myopia correction at
Fern!andez-Vega Ophthalmological Institute, Oviedo, Spain,
between December 2001 and January 2007 and regularly
returned for evaluations for at least 3 years postoperatively.
At the time of the surgery, all patients were fully informed of
the details and possible risks of the surgical procedure. Writ-
ten informed consent was obtained from all patients before
surgery in accordance with the Declaration of Helsinki,
and an institutional review board approved the study.
The inclusion criteria for pIOL implantation were a cor-
rected distance visual acuity (CDVA) of 20/50 or better, sta-
ble refraction, and a clear central cornea. The exclusion
criteria included age younger than 22 years, anterior cham-
ber depth (ACD) less than 2.8 mm, endothelial cell density
(ECD) less than 2000 cells/mm2, cataract, history of glau-
coma or retinal detachment, macular degeneration or reti-
nopathy, neuro-ophthalmic disease, and a history of ocular
inflammation.
Before pIOL implantation, patients had a complete oph-
thalmologic examination including manifest and cycloplegic
refractions, keratometry, corneal topography and pachyme-
try (Orbscan II, Bausch&Lomb), ECD (SP 3000P, Topcon Eu-
ropeMedical), slitlamp examination, Goldmann applanation
tonometry, and binocular indirect ophthalmoscopy through
dilated pupils. Cell counts were performed in a semiauto-
matic manner by the same technician. After automatic cell
detection by the instrument, the technician corrected the
edges of cells that had not been identified by the fully auto-
matic image analysis. This ensured higher reliability of
image analysis.24,25 A minimum of 100 cells was required
in each image to process the cell counting.
Phakic Intraocular Lens Size and Power Calculation
The Visian Implantable Collamer Lens pIOL for myopia is
rectangular and 7.0 mm wide. It is available in 4 overall
lengths (11.5mm, 12.0mm, 12.5mm, 13.0mm) and a dioptric
power range of !3.00 to !23.00 diopters (D). In all cases,
a model ICL V4 pIOL was implanted and the target was em-
metropia (when possible). The pIOL size was determined
based on the horizontal white-to-white (WTW) distance
and ACD, measured with the Orbscan II device following
the manufacturer’s recommendations; that is, the size was
calculated by adding 0.5 mm to the horizontal WTW mea-
surement. Power calculation for the pIOL was performed
using the modified vertex formula in the power-table soft-
ware provided by the manufacturer. The pIOL implantation
technique has been described.26,27
Follow-up
Postoperative follow-up visits were at 1 day; 1 week; 1, 3,
and 6 months; and 1 year and then yearly thereafter. Uncor-
rected distance visual acuity (UDVA), CDVA, slitlamp
examination, refraction, ECD, fundus examination, and
intraocular pressure (IOP) were performed at each visit.
For averaging, visual acuities were converted to logMAR
values; then, the means and standard deviations (SDs)
were back-calculated to Snellen acuity. The central separa-
tion between the anterior surface of the crystalline lens and
the posterior surface of the pIOL (vault) was first assessed
using an optical section during routine slitlamp examination.
Vault was classified in 5 levels by comparing the separation
between the anterior surface of the crystalline lens and the
posterior surface of the pIOL with the central corneal thick-
ness (CCT).26 A few years after the first pIOLs were im-
planted, vault was also assessed using optical coherence
tomography (OCT) (Visante, Carl Zeiss Meditec AG). In
this method, the vault was measured perpendicular to the
lens apex or at the narrowest space between both surfaces.
The percentage of ECD loss was determined as follows: en-
dothelial cell loss (%)Z (preoperative ECD ! postoperative
ECD)/preoperative ECD.
Statistical Analysis
Data analysis was performed using SPSS for Windows
software (version 16.01, SPSS, Inc.). Normality of data was
checked by the Kolmogorov-Smirnov test and analyzed
using the paired t test, Wilcoxon rank-sum test, or analysis
of variance with multiple comparisons, where appropriate,
to determine statistical differences for refractive, visual,
and adverse outcomes. Differences were considered statisti-
cally significant when the P value was less than 0.05.
RESULTS
This study cohort comprised 188 eyes of 111 patients,
of which 80 (72%)were women. Table 1 shows the pre-
operative demographic data of the patients and the
pIOL characteristics.
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Stability and Predictability of Manifest Refraction
Figure 1 shows the improvement in and stability of
the mean spherical equivalent (SE) over time. The
mean SE decreased from !11.17 G 3.40 D preopera-
tively to !0.23 G 0.50 D 1 month postoperatively
(95% confidence interval [CI], !0.15 to !0.02) and
!0.88 G 0.72 D at 5 years (95% CI, !0.68 to !1.09).
The mean change in SE throughout the follow-up was
!0.65 G 0.65 D (P!.001, Wilcoxon signed-rank test).
High levels of predictability were achieved early after
surgery; 163 eyes (86.7%) were within G0.50 D and
182 eyes (96.8%)were withinG1.00 D of the attempted
correction at the 1-month visit. The improvement was
maintained over the postoperative follow-up (r2 Z
.953 at 5 years; Figure 2). Five years postoperatively,
19 eyes (38.0%) were within G0.50 D and 31 eyes
(62.0%) were within G1.00 D of SE; 16 eyes (32.0%)
and 3 eyes (6.0%) were undercorrected by more than
1.00D and bymore than 2.00D, respectively (Figure 3).
Visual Acuity, Safety, and Efficacy
Uncorrected Distance Visual Acuity Figure 4 shows the
cumulative Snellen acuity over time. The preoperative
Snellen UDVA was 20/400 or worse in 176 eyes
(93.6%). One month after pIOL implantation, the
mean Snellen decimal UDVA was 0.77 G 0.22 (95%
CI, 0.74 to 0.80); it was 0.71 G 0.25 (95% CI, 0.67 to
0.74) and 0.69G 0.26 (95% CI, 0.64 to 0.71) at 4 years
and 5 years, respectively. At every follow-up visit, all
eyes had a UDVA of 20/80 or better, with more than
30% achieving a UDVA of 20/20 or better.
Corrected Distance Visual Acuity The mean preopera-
tive CDVA was 0.74 G 0.21 Snellen lines. All eyes
had 20/80 or better CDVA postoperatively. At 5
years, the mean Snellen decimal CDVA was 0.83 G
0.15 (95% CI, 0.79 to 0.87). The safety index (postoper-
ative CDVA/preoperative CDVA) was 1.19 G 0.27
and 1.27G 0.33 at 1 month and 5 years, respectively;
35 of 50 eyes (70.0%) had a CDVA of 20/25 or better at
5 years. The proportion of eyes with 20/20 or better
UDVA at 5 years (34.0%) was greater than the propor-
tion having a preoperative CDVA of 1.0 or better
(23.9%). The overall efficacy index (ratio of
Table 1. Preoperative patient demographics and pIOL
characteristics.
Parameter MeanG SD Range
Age (y) 33.5G 6.1 24, 45
Manifest refraction (D)
Sphere !10.76G 3.39 !20.00, !1.50
Cylinder !0.97G 0.84 !3.50, 0.00
Keratometry (D)
Steep 44.50G 1.57 40.50, 47.25
Flat 43.50G 1.23 40.00, 47.00
ECD (cells/mm2) 2695G 467 2005, 4103
ACD (mm) 3.16G 0.25 2.84, 3.80
CCT (mm) 521G 40 473, 636
WTW distance (mm) 11.72G 0.35 11.10, 13.00
Phakic IOL
Sphere (D) !14.78G 3.80 !22.50, !2.50
Size (mm) 12.2G 0.4 11.5, 13.0
Pupil (mm)
Scotopic 6.4G 0.7 4.5, 7.0
Photopic 5.0G 0.9 2.0, 6.0
ACD Z anterior chamber depth; CCT Z central corneal thickness;
ECDZ endothelial cell density; IOLZ intraocular lens; WTWZ white
to white
Figure 1. Time course (stability) of the SE after pIOL implantation
(SEZ spherical equivalent).
Figure 2. Predictability of mean SE (attempted versus achieved)
5 years after pIOL implantation.
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postoperative UDVA/preoperative CDVA) was 0.89
G 0.35 at 5 years. The CDVA was stable over time,
with no eye losing more than 2 lines. At 5 years,
5 eyes (10.0%) had no change in CDVA, 19 (38.0%)
gained 1 line, 24 (48.0%) gained 2 lines or more,
1 (2.0%) lost 1 line, and 1 lost 2 lines (Figure 5).
Endothelial Cell Density, Intraocular Pressure, and
Vault
ThemeanECDdecreased from2698G467 cells/mm2
preoperatively to 2495G 357 cells/mm2 5 years postop-
eratively, representing a mean endothelial cell loss of
7.5%. When this loss was considered cumulatively at
Figure 3. Spherical equivalent re-
fractive accuracy at 3 years, 4 years,
and 5 years.
Figure 4. Efficacy bar chart show-
ing postoperative UDVA results
in the context of preoperative
CDVA (CDVA Z corrected dis-
tance visual acuity; UDVA Z un-
corrected distance visual acuity).
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consecutive intervals through 5 years, the total 5-year
loss was 7.7% (Figure 6).
The mean IOP was 13.9 G 1.8 mm Hg preopera-
tively and 13.8G 1.5 mm Hg 5 years postoperatively.
There were no statistically significant differences in
mean IOP between visits (PO.05, paired sample t test).
The mean postoperative vault assessed at the slit-
lamp was 2.4 G 1.0 at 1 month and 2.0 G 0.7 at
5 years. The mean vault measured with OCT was 410
G 228 mm (95% CI, 361 to 459), 354 G 166 mm (95%
CI, 296 to 412), and 364 G 198 mm (95% CI, 294
to 434) at 3 years, 4 years, and 5 years, respectively;
there were no statistically significant differences in
the mean vault between follow-up visits (PZ.325,
ANOVA).
Adverse Events and Secondary Surgery
There were no intraoperative complications, and no
eye required pIOL explantation or repositioning. One
eye developed a clinically significant symptomatic
anterior subcapsular cataract 35.7 months after pIOL
implantation. The 40-year-old patient had a preopera-
tive SEof!13.50DandaCDVAof 20/40; 1month after
pIOL implantation, the SEwasC0.25D and theUDVA
was 20/32. Three years after surgery, the eye lost 2 lines
of CDVAand the vaultwas 180 mm. Simultaneous pha-
coemulsification, pIOL extraction, and Acri.Smart 366
IOL (Acri.Tech GmbH) implantation was successfully
performed. After cataract surgery, the UDVA was
20/40, the CDVAwas 20/32, and the SE was !0.75 D.
Two eyes developed an asymptomatic anterior sub-
capsular cataract 27.4 and 55.2 months, respectively,
after pIOL implantation. Both eyes lost 1 line of
CDVA over the preoperative value but had 20/25
CDVA at the last follow-up visit. Although neither
eye required cataract surgery, the patients were sched-
uled for closer follow-up.
No pigmentary glaucoma, pupillary block, or other
vision-threatening complications occurred at any time
during the follow-up; however, 3 eyes had amild tran-
sient increase in IOP (up to 27 mmHg) during the first
3 months.
DISCUSSION
Most studies of pIOL implantation report short-term
clinical outcomes (up to 1 or 2 years), and few have
spanned 3 or more years to allow observation of the
long-term clinical and refractive results.1,22,23 In the
present study, we confirmed the very good results in
all measures of safety, efficacy, predictability, and
stability of Visian Implantable Collamer Lens pIOL
implantation to correct moderate to high myopia
throughout a 5-year follow-up. The outcomes were
consistent between patients and between follow-up
visits, with most eyes maintaining or improving
CDVA and no eye losing more than 2 lines. The safety
index was higher than 1.18 at all postoperative visits.
There was also an improvement in UDVA; more
than 30% of eyes achieved a UDVA of 20/20 or better
at all follow-up visits, and the mean change in SE
between visits was approximately 0.65 D up to 5 years.
Clinical results with the earlier version of the pIOL
we evaluated in this study confirm that the implanta-
tion procedure is a feasible treatment option for
Figure 5. Changes in CDVA (safety) over the follow-up
(CDVAZ corrected distance visual acuity).
Figure 6. Cumulative cell loss after pIOL implantation.
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various ranges of ametropia and that it gives excellent
visual and refractive results, even if some complica-
tions occurred.20,28–30 In addition, when compared
with the visual outcomes of laser keratorefractive pro-
cedures, pIOL implantation seems to provide better
visual performance with equal or better efficacy and
safety.31–35 In a 3-year FDA myopic Implantable Col-
lamer Lens study of 526 eyes of 294 patients,1 94.7%
of patients had a UDVA of 20/40 or better, 67.5%
were within G0.50 D of the predicted refraction, and
88.2%werewithinG1.00 D of the predicted refraction.
The mean improvement in CDVA was between 0.5
lines and 0.6 lines. Three eyes (0.8%) had a decrease
in CDVA of 2 lines, 15 eyes (2.9%) required an addi-
tional refractive procedure, 14 eyes (2.7%) developed
early asymptomatic anterior subcapsular cataract,
and 3 eyes (0.6%) required pIOL removal with cataract
extraction and IOL implantation.
Lackner et al.,22 in a 3-year follow-up study of 76
eyes (mean SE !16.5 G 5.6; range !5.5 to !33.4 D)
found an improvement in UDVA from 0.04 G 0.04
preoperatively to 0.35 G 0.28 Snellen lines at the last
patient visit; the mean postoperative refraction was
0.4 D (range 0.0 to 2.2 D). In that study, 11 eyes
(14.5%) developed lens opacification that was signifi-
cantly progressive in 5 eyes, probably as a result of sur-
gical trauma and older age.
In a study by Kamiya et al.23 of 56 eyes of 34 patients
(mean SE !9.8G 3.0 D; range !4.00 to !15.25 D), the
mean UDVA and CDVA improved from 1.49 G 0.22
logMAR and !0.15 G 0.08 logMAR, respectively,
preoperatively to !0.03G 0.23 and !0.21G 0.09, re-
spectively, 4 years after surgery. Five eyes (9%) lost
1 line of CDVA; no eye lost 2 or more lines. Forty-
four eyes (79%) were withinG0.50 D of the attempted
correction, and 52 eyes (93%) were within G1.00 D.
The mean percentage of endothelial cell loss was
3.7% 4 years after surgery.
The results in the present study are comparable to
those previously reported. In our study, 70.0% (35/50)
of eyes achieved aCDVAof 20/25 or better 5 years after
surgery. The greatest loss of CDVAwas 2 lines in 1 eye
that developed a clinically significant symptomatic
anterior subcapsular cataract. Regarding refractive out-
comes, a smaller proportion of eyes in this study than in
previous studies were withinG0.50 D andG1.00 D of
the attempted correction; this is because 9.0% of eyes
(17/188) in our study had a preoperative SE higher
than !15.00 D and 8.5% (16/188) had refractive cylin-
der of 2.00 D or higher that could not be fully corrected
by the strongest available pIOL power. These cases
were targeted for undercorrection. However, the corre-
lation between the attempted refraction and the
achieved refraction was high, with 82.6% (152/184) of
eyes and 62.0% (31/50) of eyes being within G1.00 D
of the desired refraction at 3 years and 5 years, respec-
tively. The SE was also stable throughout the follow-
up, with a slight tendency toward a myopic shift. The
shift might be explained by the biometric changes that
occur in myopic patients36 or by the decrease in vault,27
narrowing the gapbetween the pIOL and the crystalline
lens and increasing the effective power of the optical
system.
The most significant concern about pIOL implanta-
tion is cataract formation. In the Implantable Collamer
Lens FDA trial,1 the rate of cataract formation was
2.1%. Other studies report a secondary cataract forma-
tion rate between 1.6%37 and 14.5%.22 In a 5-year
follow-up study by Sanders,21 anterior subcapsular
opacities occurred in 5.9% of 526 eyes, with 1.3% pro-
gressing to clinically significant cataract; progression
to clinically significant cataract generally occurred in
patients with very high myopia or in older patients.
In a study by Alfonso et al.27 of 964 myopic eyes of
531 patients, anterior subcapsular cataract developed
in 13 eyes (1.3%); the cataract developed before 1
year in 2 eyes, between 2 years and 3 years in 7 eyes,
and after 3 years in 4 eyes, indicating that patient
age and lower vault are the most important factors
in pIOL-induced cataract. In a recent metaanalysis
by Chen et al.38 of 6338 eyes that included angle-
supported, iris-supported, and posterior chamber
pIOLs, the incidence of cataract formation in eyes
with the Implantable Collamer Lens pIOL (1933
eyes; 218 V2 or earlier models, 249 V3 models, 877
V4 models, and 589 design not specified) was 8.48%.
Early cataract formation was related to surgical
trauma and late cataract formation, to pIOL–crystal-
line lens contact.
In the present study, 3 eyes (1.6%) developed late
anterior subcapsular cataract. The cataract was clini-
cally significant in 1 case, leading to pIOL removal
and phacoemulsification with IOL implantation. This
eye was highly myopic (!13.50 D) and had a vault
of 180 mm 3 years after surgery. In the other 2 eyes
with anterior subcapsular cataract, the loss of CDVA
was 1 Snellen line and there was no need for a second
surgery, although the patients were scheduled for
closer follow-up. The main theories of the cause of
late anterior subcapsular cataract development are
absent or lower vault and the tendency of the vault
to decrease slightly over time, causing constant or
intermittent pIOL–crystalline lens contact.27,39,40 A
limitation of our study was that it was not possible
to measure vault objectively with OCT from the first
day after pIOL implantation; thus, we could not objec-
tively measure the changes in vault over time. How-
ever, the mean vault assessed at the slitlamp and
compared with CCT decreased slightly over time
(mean vault level 2.4 G 1.0 at 1 month and 2.0G 0.7
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at 5 years), which was confirmed with OCT (mean
vault 410 G 228 mm at 3 years and 364 G 198 mm at
5 years).
Another limitation of our study is the small number
of patients who completed the 5-year follow-up. Most
patients were lost to follow-up between the 4-year and
5-year visits, with 184 eyes (97.9%) available for the
3-year visit. This is usual with successful treatments
such as pIOL implantation because patients who are
satisfied with the outcomes often do not return for
the recommended regular visits. Although this may
have had some impact on the final results, a higher
follow-up rate would likely improve the results in
areas such as efficacy, predictability, safety, and vault.
A significant decrease in vault can cause changes in vi-
sual acuity and in the worst cases, cataract formation.
Thus, we believe that a better follow-up rate would
have improved our results.Although our resultsmatch
well with those in previous studies with a similar sam-
ple size, this limitation does have some implications.
For example, the trend toward regression in myopia
over time (mean 0.88 D at 5 years) might be because
more patients with regression than patients who had
no change in refraction attended the follow-up visits.
Endothelial cell loss is another concern with pIOL
implantation. The rate of postoperative endothelial
cell loss has been reported to be approximately 6.5%
at 2 years28 and 6.09% at 3 years.41 Others report
a mean endothelial cell loss of 3.7% at 4 years.23 In
the FDA clinical study, Edelhauser et al.17 found a cu-
mulative endothelial cell loss between 8.4% and 8.9%
over the first 3 years and between 8.4% and 9.5%
over the first 4 years, with an endothelial cell loss
rate of 2% to 3% per year over the first 3 years of
follow-up. There was a 0.1% increase in cells between
3 years and 4 years, suggesting that endothelial re-
modeling and stability may have been achieved by
3 years. We found a mean endothelial cell loss of ap-
proximately 1.5% per year and a mean cumulative en-
dothelial cell loss of 7.7% at 5 years. The ongoing cell
loss was more noticeable during the first year (5.5%),
after which it decreased and stabilized. The percentage
of ECD loss with age is reported to be 0.5 to 0.6 per
year.42,43 Thus, our results may be explained by cor-
neal remodeling after the surgical procedure rather
than by continuing cell loss due to the effect of aging.
Another important concern afterpIOL implantation is
increased IOP, which in most cases is associated with
significant angle narrowing by forward iris displace-
ment44orwithchronicpigmentdispersion.18 In thepres-
ent study, 3 eyes (1.6%) had a mild transient increase in
IOP (up to27mmHg); the eyeshadbetween15.00Dand
17.00 D of preoperative myopia and had high initial
pIOL vault; none of those eyes needed a second surgical
procedure or prolonged topical medication.
In summary, our long-term results suggest that
Visian Implantable Collamer Lens pIOL implantation
to correct moderate to high myopia is a safe and effec-
tive procedure that provides predictable and stable
refractive results over the long term; in this case,
over 5 years. The rates of postoperative complications
were low, and there were no vision-threatening com-
plications throughout the follow-up. Future studies
with a longer follow-up are necessary to assess late-
onset complications, specifically in the development
of anterior lens opacities and the change in vault
over time.
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